Form 4: Lucid Diagnostics CEO Aklog Lishan Reports Acquisition of 300,000 Shares of Common Stock

Lucid Diagnostics CEO Aklog Lishan reports acquiring 300,000 shares of common stock and discloses beneficial ownership of 1,466,627 shares.

Summary

• On February 20, 2025, Lishan Aklog, CEO of Lucid Diagnostics Inc., acquired 300,000 shares of common stock.
• The acquisition was through a grant of restricted stock under the Issuer's 2018 Equity Plan.
• The restricted stock vests on May 20, 2028, and is subject to forfeiture if the service period is not completed.
• The reported transaction also reflects Dr. Aklog's beneficial ownership of 1,466,627 shares of Lucid common stock.
• This includes 142,227 shares distributed by PAVmed on February 15, 2024, representing his pro rata share of Lucid common stock distributed to PAVmed shareholders.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by the CEO. The acquisition itself could be seen as a positive sign, but it's not a major event.

Positives

• The CEO's acquisition of a significant number of shares could be interpreted as a sign of confidence in the company's future prospects.

Risks

• The restricted stock is subject to forfeiture if the service period is not completed, which could be a risk if the CEO were to leave the company before the vesting date.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's confidence in the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates the CEO's investment in the company.

Key Dates

Keywords

Lucid Diagnostics, Lishan Aklog, Form 4, Beneficial Ownership, Restricted Stock, Equity Plan, PAVmed, LUCD